Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
Erasca (Nasdaq: ERAS) reported Q4 and full-year 2025 results and business updates on March 12, 2026. The company highlighted promising early Phase 1 activity for ERAS-0015, planned H1 2026 monotherapy data for ERAS-0015 and H2 2026 data for ERAS-4001, a $258.8M upsized financing, and $341.8M cash at 12/31/2025.
Management expects pro forma cash of $434M to fund operations into H2 2028; issued U.S. composition patents protect ERAS-0015 and ERAS-4001 through 2043.
Erasca (Nasdaq: ERAS) exercised its option to expand the ERAS-0015 license with Joyo to include China, Hong Kong, and Macau, securing worldwide rights for the pan-RAS molecular glue. Erasca will make a one-time payment tied to Joyo’s development stage and plans unified global development.
ERAS-0015 has shown promising early clinical activity across multiple tumor types and RAS mutations at low doses; initial Phase 1 monotherapy data are expected in H1 2026.
Erasca (Nasdaq: ERAS) and Tango Therapeutics announced a clinical collaboration and supply agreement to evaluate Erasca’s pan-RAS molecular glue ERAS-0015 combined with Tango’s PRMT5 inhibitor vopimetostat in a Phase 1/2 trial for MTAP-deleted pancreatic cancer and MTAP-deleted RAS-mutant NSCLC.
Tango will sponsor the trial; Erasca will supply ERAS-0015 at no cost. The collaboration is mutually non-exclusive and each company retains commercial rights to its compound.
Erasca (Nasdaq: ERAS) announced issuance of U.S. Patent No. 12,552,813 covering the composition of matter for its pan-KRAS inhibitor ERAS-4001, with protection until at least June 2043. The patent broadens Erasca’s RAS IP portfolio and supports its ERAS-4001 program; additional patents are pending. Erasca expects Phase 1 monotherapy data for ERAS-0015 in 1H 2026 and for ERAS-4001 in 2H 2026.
Erasca (Nasdaq: ERAS) announced management will present and hold one-on-one investor meetings at two February 2026 conferences: Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12) and Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25-26).
Fireside chat times: Feb 12 at 1:00 PM ET (Guggenheim) and Feb 26 at 11:20 AM ET (Oppenheimer). Live audio webcasts and archived replays will be available at Erasca.com/events for 30 days following each webcast.
Erasca (Nasdaq: ERAS) closed an upsized public offering of 25,875,000 shares of common stock on January 23, 2026, which included 3,375,000 shares sold pursuant to the underwriters' full exercise of their option.
The shares were sold at $10.00 per share, generating approximately $258.8 million in gross proceeds before underwriting discounts, commissions, and offering expenses. All shares were sold by Erasca.
Erasca intends to use net proceeds, together with existing cash and marketable securities, to fund research and development of its product candidates, development programs, working capital, and other general corporate purposes.
Erasca (Nasdaq: ERAS) priced an upsized public offering of 22,500,000 shares of common stock at $10.00 per share, generating expected gross proceeds of $225.0 million. The company granted the underwriters a 30‑day option to purchase up to an additional 3,375,000 shares at the offering price, less underwriting discounts and commissions.
The offering is expected to close on January 23, 2026, subject to customary closing conditions. Net proceeds, together with existing cash and securities, are intended to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes.
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. The company said it will use net proceeds together with existing cash and marketable securities to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes. The offering will be made under a shelf registration statement declared effective on August 22, 2025, and a preliminary prospectus supplement will be filed with the SEC. There is no assurance the offering will be completed or as to final size or terms.
Erasca (NASDAQ: ERAS) reported early Phase 1 clinical progress for its RAS franchise. ERAS-0015 showed ongoing responses including two confirmed partial responses and one unconfirmed partial response observed at 8 mg QD, with favorable safety (no dose-limiting toxicities) and linear pharmacokinetics; data cutoff was January 7, 2026. INDs for ERAS-0015 and ERAS-4001 were cleared in May 2025. Initial Phase 1 monotherapy topline data for ERAS-0015 are planned for H1 2026, with expansion and combination cohorts in H2 2026 and additional data in 2027. ERAS-4001 monotherapy topline data are planned for H2 2026 with cohorts in 2027.
Erasca (Nasdaq: ERAS) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will present on Tuesday, January 13, 2026 at 1:30 PM PT, participate in one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.